RxDoctor Payments Data

Laura Porch

Family · Cordova, TNNPI 1487609509

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 40.0% of the total. Among family clinicians in TN with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$148,007in general payments, 2019–2025

Across 1,635 payments — averaging $90.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$59K
  • AbbVie$36K
  • Lundbeck LLC$10K
  • Amneal Pharmaceuticals LLC$10K
  • Livanova USA, Inc.$7K
  • Abbott$3K
  • plus $22K from 54 others

What the payments were for

  • Consulting fees$26,55818%
  • Speaking & faculty fees$74,41650%
  • Travel & lodging$18,68413%
  • Food & beverage$28,14219%
  • Education$2080%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurocrine Biosciences, Inc.154$59,166
AbbVie(2 entities)291$36,348
Lundbeck LLC50$10,085
Amneal Pharmaceuticals LLC83$9,647
Livanova USA, Inc.24$7,334
Abbott25$3,347
Novartis103$2,875
Boston Scientific11$2,156
MDD US Operations, LLC22$1,864
Amgen(2 entities)79$1,349
Pfizer102$1,059
UCB, Inc.41$975
EMD Serono, Inc.52$931
Biogen44$758
Argenx US, Inc.34$718
Teva Pharmaceuticals USA, Inc.58$709
AstraZeneca(2 entities)26$678
Bristol Myers Squibb42$658
TG Therapeutics, Inc.25$593
Genentech USA, Inc.36$586
Lilly USA, LLC32$478
Acadia Pharmaceuticals Inc30$468
Eisai Inc.22$468
SK Life Science, Inc.29$468
Otsuka America Pharmaceutical, Inc.22$332
Medtronic6$332
Neurelis, Inc.11$271
Alnylam Pharmaceuticals Inc.14$255
Grifols USA, LLC13$254
Harmony Biosciences LLC10$250
CSL Behring12$214
Biohaven Pharmaceutical Holding Company Ltd.15$207
Axsome Therapeutics, Inc.4$201
Acorda Therapeutics, Inc10$182
C2n Diagnostics, LLC8$140
Biohaven Pharmaceuticals, Inc.10$134
Jazz Pharmaceuticals Inc.6$124
Banner Life Sciences, LLC8$122
Sanofi5$108
Sunovion Pharmaceuticals Inc.8$99
Tanabe Pharma America, Inc.6$94
Johnson & Johnson(2 entities)4$92
Adamas Pharmaceuticals, Inc.4$90
Avanir Pharmaceuticals, Inc.5$87
Scilex Pharmaceuticals Inc.4$69
Insightec,inc1$67
Mallinckrodt Hospital Products Inc.3$55
Merz Pharmaceuticals, LLC2$51
Ipsen Biopharmaceuticals, Inc2$41
Catalyst Pharmaceuticals, Inc.2$39
ANI Pharmaceuticals, Inc.2$36
Kyowa Kirin, Inc.2$36
Akcea Therapeutics, Inc.2$30
Cycle Pharmaceuticals Inc2$28
Takeda Pharmaceuticals U.S.A., Inc.1$23
Nevro Corp.1$23
Averitas Pharma Inc.1$20
Sanofi-aventis U.S. LLC1$18
Corium, LLC2$17
Supernus Pharmaceuticals, Inc.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$148,007 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$72,490
Medicare patients
304
Services billed
3,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BetaseronInterferon Beta-1b14$119,139
GocovriAmantadine Hcl28$71,936
RytaryCarbidopa/Levodopa48$44,005
FycompaPerampanel29$43,360
Nurtec OdtRimegepant Sulfate25$36,939
BriviactBrivaracetam14$24,521
Keppra XrLevetiracetam11$16,858
NeuproRotigotine18$14,994
Lacosamide41$8,861
Levetiracetam121$4,535
Oxcarbazepine46$4,098
Clorazepate Dipotassium40$3,951
Carbamazepine ErCarbamazepine16$3,732
Duloxetine Hcl40$3,508
Levetiracetam ErLevetiracetam37$3,239

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MDD US Operations, LLCGocovri$1,864$71,93628 claims
Amneal Pharmaceuticals LLCRytary$9,647$44,00548 claims
Eisai Inc.Fycompa$468$43,36029 claims
UCB, Inc.Briviact, Neupro$975$39,51532 claims
PfizerNurtec Odt$1,059$36,93925 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Cordova

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →